Steward C D, Rasheed J K, Hubert S K, Biddle J W, Raney P M, Anderson G J, Williams P P, Brittain K L, Oliver A, McGowan J E, Tenover F C
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
J Clin Microbiol. 2001 Aug;39(8):2864-72. doi: 10.1128/JCM.39.8.2864-2872.2001.
Extended-spectrum beta-lactamases (ESBLs) are enzymes found in gram-negative bacilli that mediate resistance to extended-spectrum cephalosporins and aztreonam. In 1999, the National Committee for Clinical Laboratory Standards (NCCLS) published methods for screening and confirming the presence of ESBLs in Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli. To evaluate the confirmation protocol, we tested 139 isolates of K. pneumoniae that were sent to Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) from 19 hospitals in 11 U.S. states. Each isolate met the NCCLS screening criteria for potential ESBL producers (ceftazidime [CAZ] or cefotaxime [CTX] MICs were > or =2 microg/ml for all isolates). Initially, 117 (84%) isolates demonstrated a clavulanic acid (CA) effect by disk diffusion (i.e., an increase in CAZ or CTX zone diameters of > or =5 mm in the presence of CA), and 114 (82%) demonstrated a CA effect by broth microdilution (reduction of CAZ or CTX MICs by > or =3 dilutions). For five isolates, a CA effect could not be determined initially by broth microdilution because of off-scale CAZ results. However, a CA effect was observed in two of these isolates by testing cefepime and cefepime plus CA. The cefoxitin MICs for 23 isolates that failed to show a CA effect by broth microdilution were > or =32 microg/ml, suggesting either the presence of an AmpC-type beta-lactamase or porin changes that could mask a CA effect. By isoelectric focusing (IEF), 7 of the 23 isolates contained a beta-lactamase with a pI of > or =8.3 suggestive of an AmpC-type beta-lactamase; 6 of the 7 isolates were shown by PCR to contain both ampC-type and bla(OXA) genes. The IEF profiles of the remaining 16 isolates showed a variety of beta-lactamase bands, all of which had pIs of < or =7.5. All 16 isolates were negative by PCR with multiple primer sets for ampC-type, bla(OXA), and bla(CTX-M) genes. In summary, 83.5% of the K. pneumoniae isolates that were identified initially as presumptive ESBL producers were positive for a CA effect, while 5.0% contained beta-lactamases that likely masked the CA effect. The remaining 11.5% of the isolates studied contained beta-lactamases that did not demonstrate a CA effect. An algorithm based on phenotypic analyses is suggested for evaluation of such isolates.
超广谱β-内酰胺酶(ESBLs)是在革兰氏阴性杆菌中发现的酶,可介导对超广谱头孢菌素和氨曲南的耐药性。1999年,美国国家临床实验室标准委员会(NCCLS)发布了在肺炎克雷伯菌、产酸克雷伯菌和大肠埃希菌中筛选和确认ESBLs存在的方法。为评估确认方案,我们检测了从美国11个州的19家医院送至重症监护抗菌药物耐药性流行病学项目(ICARE)的139株肺炎克雷伯菌分离株。每株分离株均符合NCCLS对潜在ESBL产生菌的筛选标准(所有分离株的头孢他啶[CAZ]或头孢噻肟[CTX] MIC均≥2 μg/ml)。最初,117株(84%)分离株通过纸片扩散法显示克拉维酸(CA)效应(即在有CA存在时,CAZ或CTX抑菌圈直径增加≥5 mm),114株(82%)通过肉汤微量稀释法显示CA效应(CAZ或CTX MIC降低≥3倍稀释度)。对于5株分离株,由于CAZ结果超出范围,最初无法通过肉汤微量稀释法确定CA效应。然而,通过检测头孢吡肟以及头孢吡肟加CA,在其中2株分离株中观察到了CA效应。23株未通过肉汤微量稀释法显示CA效应的分离株的头孢西丁MIC≥32 μg/ml,提示存在AmpC型β-内酰胺酶或孔蛋白改变,可能掩盖了CA效应。通过等电聚焦(IEF),23株分离株中有7株含有pI≥8.3的β-内酰胺酶,提示为AmpC型β-内酰胺酶;7株中的6株经PCR检测显示同时含有ampC型和bla(OXA)基因。其余16株分离株IEF图谱显示出多种β-内酰胺酶条带,其pI均≤7.5。用针对ampC型、bla(OXA)和bla(CTX-M)基因的多组引物进行PCR检测,所有16株分离株均为阴性。总之,最初被鉴定为推定ESBL产生菌的肺炎克雷伯菌分离株中,83.5%对CA效应呈阳性,而5.0%含有可能掩盖CA效应的β-内酰胺酶。其余11.5%的研究分离株含有未显示CA效应的β-内酰胺酶。建议采用基于表型分析的算法来评估此类分离株。